MeSH term
Frequency | Condition_Probility | Animals | 54 | 0.0 |
DNA Adducts | 3 | 4.0 |
DNA Damage | 2 | 0.0 |
Gene Expression | 7 | 0.0 |
Humans | 221 | 0.0 |
Adult | 58 | 0.0 |
Aged | 52 | 0.0 |
Arylamine N-Acetyltransferase/*biosynthesis | 2 | 66.0 |
Blotting, Western | 9 | 0.0 |
Case-Control Studies | 37 | 0.0 |
Female | 90 | 0.0 |
Immunohistochemistry | 5 | 0.0 |
Male | 83 | 0.0 |
Middle Aged | 75 | 0.0 |
RNA, Messenger/analysis | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 9 | 0.0 |
Smoking/*metabolism | 2 | 4.0 |
Acetylation | 61 | 12.0 |
Alleles | 37 | 0.0 |
Arylamine N-Acetyltransferase/*genetics | 51 | 24.0 |
Comparative Study | 20 | 0.0 |
European Continental Ancestry Group/*genetics | 2 | 0.0 |
Genetic Predisposition to Disease | 17 | 0.0 |
Genotype | 85 | 0.0 |
Isoenzymes/*genetics | 21 | 4.0 |
Polymorphism, Genetic/genetics | 4 | 0.0 |
Research Support, Non-U.S. Gov't | 139 | 0.0 |
Risk Factors | 41 | 0.0 |
Acetyltransferases/*genetics/metabolism | 9 | 52.0 |
Aminobiphenyl Compounds/*metabolism | 2 | 33.0 |
Arylamine N-Acetyltransferase/*metabolism | 18 | 56.0 |
Carcinogens/*metabolism | 9 | 11.0 |
Disease Susceptibility | 6 | 0.0 |
Mutagens/*metabolism | 5 | 13.0 |
Phenotype | 37 | 0.0 |
*Polymorphism, Genetic | 36 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 71 | 0.0 |
Variation (Genetics) | 8 | 0.0 |
Acetyltransferases/*genetics | 30 | 56.0 |
*Diet | 2 | 0.0 |
*Genetic Predisposition to Disease | 11 | 1.0 |
Glutathione Transferase/*genetics | 10 | 1.0 |
Incidence | 5 | 0.0 |
*Meat | 6 | 14.0 |
Netherlands/epidemiology | 3 | 2.0 |
Polymorphism, Genetic | 34 | 0.0 |
Prospective Studies | 4 | 0.0 |
Sex Factors | 4 | 0.0 |
Smoking/*adverse effects | 10 | 4.0 |
Acetyltransferases/genetics/*metabolism | 2 | 8.0 |
Amines/*pharmacokinetics | 4 | 100.0 |
Arylamine N-Acetyltransferase/genetics/metabolism | 4 | 26.0 |
*Arylsulfotransferase | 2 | 5.0 |
Biotransformation | 30 | 5.0 |
Gene Expression Regulation, Bacterial | 2 | 3.0 |
Gene Expression Regulation, Enzymologic | 7 | 0.0 |
Imidazoles/metabolism | 2 | 15.0 |
Isoenzymes/genetics/metabolism | 4 | 2.0 |
Mutagenicity Tests | 6 | 3.0 |
Amines/*toxicity | 3 | 27.0 |
Carcinogens/*toxicity | 3 | 2.0 |
Cytochrome P-450 CYP1A2/metabolism | 3 | 3.0 |
Recombinant Proteins/metabolism | 10 | 0.0 |
Aged, 80 and over | 14 | 0.0 |
Laryngeal Neoplasms/*genetics | 2 | 11.0 |
*Polymorphism, Restriction Fragment Length | 4 | 0.0 |
Occupational Exposure/*adverse effects | 3 | 3.0 |
Amino Acid Sequence | 13 | 0.0 |
Base Sequence | 36 | 0.0 |
Cloning, Molecular | 21 | 0.0 |
English Abstract | 6 | 0.0 |
Mice | 18 | 0.0 |
Molecular Sequence Data | 33 | 0.0 |
Mutation | 14 | 0.0 |
Polymerase Chain Reaction | 35 | 0.0 |
Species Specificity | 3 | 0.0 |
Arylamine N-Acetyltransferase/*genetics/metabolism | 16 | 30.0 |
Glutathione Transferase/genetics | 13 | 4.0 |
Isoenzymes/*genetics/metabolism | 7 | 11.0 |
Odds Ratio | 10 | 0.0 |
Child | 4 | 0.0 |
Child, Preschool | 4 | 0.0 |
DNA Repair/*genetics | 2 | 0.0 |
Infant | 2 | 0.0 |
NAD(P)H Dehydrogenase (Quinone)/*genetics | 2 | 2.0 |
Survival Rate | 2 | 0.0 |
Xenobiotics/metabolism | 6 | 13.0 |
Cookery | 3 | 5.0 |
Cytochrome P-450 CYP1A2/*genetics | 2 | 5.0 |
Diet | 5 | 1.0 |
Heterocyclic Compounds/metabolism | 2 | 40.0 |
Polymorphism, Genetic/*genetics | 15 | 1.0 |
Quinolines/*metabolism | 3 | 17.0 |
Sequence Analysis, DNA | 9 | 0.0 |
Acetyltransferases/metabolism | 3 | 4.0 |
Glutathione Transferase/metabolism | 5 | 0.0 |
Pharmaceutical Preparations/*metabolism | 3 | 3.0 |
Sulfotransferases/metabolism | 3 | 21.0 |
Enzyme Induction | 3 | 0.0 |
Acetyltransferases/genetics/metabolism | 2 | 18.0 |
Adolescent | 13 | 0.0 |
Cell Line | 9 | 0.0 |
Quinolines/*pharmacokinetics | 3 | 30.0 |
Arylamine N-Acetyltransferase/genetics | 14 | 23.0 |
Cytochrome P-450 CYP1A1/genetics | 7 | 7.0 |
DNA Adducts/*analysis | 4 | 9.0 |
*Genes, ras | 2 | 0.0 |
Isoenzymes/genetics | 9 | 2.0 |
*Mutation | 6 | 0.0 |
*Alleles | 8 | 0.0 |
*Arylamine N-Acetyltransferase | 11 | 100.0 |
Head and Neck Neoplasms/enzymology/*genetics | 2 | 33.0 |
Polymerase Chain Reaction/methods | 2 | 0.0 |
Gene Frequency | 24 | 0.0 |
*Ligases | 2 | 1.0 |
Loss of Heterozygosity | 2 | 0.0 |
Polymorphism, Restriction Fragment Length | 16 | 0.0 |
Polymorphism, Single-Stranded Conformational | 2 | 0.0 |
*Tumor Suppressor Proteins | 2 | 0.0 |
*Ubiquitin-Protein Ligases | 2 | 0.0 |
Acetyltransferases/*genetics/*metabolism | 2 | 40.0 |
Carcinogens/metabolism | 8 | 25.0 |
Enzyme Stability | 7 | 3.0 |
Heat | 3 | 0.0 |
Protein Denaturation | 3 | 1.0 |
Colorectal Neoplasms/*epidemiology/*genetics | 2 | 40.0 |
Electrophoresis, Polyacrylamide Gel | 5 | 0.0 |
In Situ Hybridization | 4 | 0.0 |
Molecular Weight | 2 | 0.0 |
Sequence Homology, Amino Acid | 5 | 0.0 |
4-Aminobenzoic Acid/pharmacokinetics | 2 | 100.0 |
Breast/*enzymology | 2 | 13.0 |
Isoenzymes/*metabolism | 10 | 3.0 |
Kinetics | 25 | 0.0 |
Substrate Specificity | 13 | 0.0 |
Tumor Cells, Cultured | 6 | 0.0 |
Models, Biological | 4 | 0.0 |
DNA Adducts/*metabolism | 3 | 6.0 |
Mass Fragmentography | 2 | 0.0 |
Enzyme Inhibitors/pharmacology | 4 | 0.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Sulfotransferases/*genetics | 3 | 8.0 |
*Chromosomes, Human, Pair 8 | 2 | 0.0 |
Bladder Neoplasms/enzymology/*genetics | 3 | 23.0 |
Genetic Predisposition to Disease/genetics | 2 | 0.0 |
Haplotypes | 2 | 0.0 |
Occupational Exposure | 2 | 2.0 |
Smoking/adverse effects | 7 | 2.0 |
Acetyltransferases/genetics | 8 | 21.0 |
Cytochrome P-450 CYP2D6/genetics | 4 | 12.0 |
Logistic Models | 3 | 0.0 |
Chromosome Mapping | 5 | 0.0 |
Japan | 4 | 0.0 |
*Polymorphism, Single Nucleotide | 2 | 0.0 |
Catalytic Domain | 2 | 0.0 |
Conserved Sequence | 2 | 0.0 |
Protein Conformation | 2 | 0.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Breast Neoplasms/*enzymology/epidemiology/*genetics | 2 | 50.0 |
Environmental Exposure | 4 | 2.0 |
DNA Primers | 10 | 0.0 |
Genetic Predisposition to Disease/epidemiology | 2 | 2.0 |
Risk Assessment | 6 | 0.0 |
Arylamine N-Acetyltransferase/antagonists & inhibitors/*metabolism | 2 | 40.0 |
Centrifugation, Density Gradient | 2 | 0.0 |
Chromatography, High Pressure Liquid | 4 | 0.0 |
Placenta/*enzymology | 4 | 5.0 |
Arylamine N-Acetyltransferase/*antagonists & inhibitors/metabolism | 2 | 40.0 |
In Vitro | 12 | 0.0 |
Organ Specificity | 3 | 0.0 |
Arylamine N-Acetyltransferase/*genetics/*metabolism | 7 | 50.0 |
*Pharmacogenetics | 3 | 6.0 |
Smoking/*adverse effects/metabolism | 2 | 28.0 |
Neoplasms/*genetics | 2 | 0.0 |
Molecular Biology | 4 | 1.0 |
*Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Homozygote | 2 | 0.0 |
Pilot Projects | 4 | 0.0 |
COS Cells | 3 | 0.0 |
Escherichia coli | 2 | 0.0 |
DNA, Complementary | 3 | 0.0 |
Cattle | 3 | 0.0 |
Cytosol/metabolism | 8 | 1.0 |
DNA/metabolism | 3 | 0.0 |
Isoenzymes/metabolism | 2 | 0.0 |
Liver/metabolism | 3 | 0.0 |
Mice, Inbred Strains | 3 | 0.0 |
Rats | 8 | 0.0 |
Rats, Inbred F344 | 2 | 0.0 |
*Chromosome Aberrations | 3 | 0.0 |
*Genotype | 4 | 1.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 11 | 0.0 |
Smoking/genetics | 2 | 10.0 |
Ethnic Groups | 4 | 1.0 |
4-Aminobenzoic Acid/metabolism | 12 | 92.0 |
Asian Continental Ancestry Group/genetics | 3 | 0.0 |
Isoenzymes/*genetics/*metabolism | 3 | 18.0 |
Lymphocytes/enzymology | 2 | 2.0 |
Smoking | 6 | 1.0 |
Asia/epidemiology | 2 | 12.0 |
Linkage (Genetics) | 3 | 0.0 |
DNA, Complementary/metabolism | 2 | 0.0 |
Placenta/*metabolism | 2 | 1.0 |
Tissue Distribution | 4 | 0.0 |
Genetic Screening | 2 | 0.0 |
Heterozygote | 4 | 0.0 |
Colorectal Neoplasms/genetics | 2 | 4.0 |
Epidemiology, Molecular | 2 | 2.0 |
Postmenopause | 4 | 2.0 |
Fetal Blood/metabolism | 2 | 3.0 |
Infant, Newborn | 3 | 0.0 |
Pregnancy | 8 | 0.0 |
Questionnaires | 3 | 0.0 |
Glutathione Transferase/*genetics/metabolism | 3 | 3.0 |
Amines/*metabolism | 4 | 22.0 |
Cells, Cultured | 5 | 0.0 |
Bladder Neoplasms/etiology | 3 | 42.0 |
Analysis of Variance | 2 | 0.0 |
Chi-Square Distribution | 2 | 0.0 |
*Eukaryotic Initiation Factor-4G | 3 | 30.0 |
Protein Binding | 2 | 0.0 |
4-Aminobenzoic Acid/pharmacology | 2 | 66.0 |
Sulfamethazine/pharmacology | 2 | 66.0 |
Time Factors | 5 | 0.0 |
Cell Transformation, Neoplastic/genetics | 2 | 0.0 |
Rabbits | 7 | 0.0 |
Adenocarcinoma/*genetics | 2 | 1.0 |
Colorectal Neoplasms/*genetics | 6 | 2.0 |
DNA Mutational Analysis | 3 | 0.0 |
Erythrocytes/*enzymology | 3 | 0.0 |
Chromosomes, Human, Pair 8/genetics | 2 | 2.0 |
Genetics, Population | 2 | 0.0 |
Liver/*metabolism | 2 | 0.0 |
Sulfamethazine/metabolism | 7 | 87.0 |
*Aneuploidy | 2 | 2.0 |
Folic Acid/*metabolism | 4 | 8.0 |
Glutamates/*metabolism | 2 | 20.0 |
Mice, Inbred C57BL | 5 | 0.0 |
DNA Adducts/metabolism | 2 | 5.0 |
Imidazoles/*metabolism | 2 | 6.0 |
Pyridines/*metabolism | 2 | 20.0 |
Quinoxalines/*metabolism | 2 | 22.0 |
Bladder Neoplasms/*genetics/pathology | 2 | 5.0 |
Chromosome Deletion | 2 | 0.0 |
Genetic Markers | 2 | 0.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Neoplasm Staging | 2 | 0.0 |
Arylamine N-Acetyltransferase/*biosynthesis/genetics | 2 | 100.0 |
Cytosol/enzymology | 6 | 3.0 |
Fluorenes/metabolism | 4 | 36.0 |
Mice, Transgenic | 4 | 0.0 |
Prostate/*enzymology | 2 | 1.0 |
Arylamine N-Acetyltransferase/*physiology | 3 | 60.0 |
Fluorenes/pharmacokinetics/toxicity | 2 | 100.0 |
Isoenzymes/*physiology | 2 | 6.0 |
Prostatic Neoplasms/*enzymology/*genetics | 2 | 28.0 |
Risk | 6 | 0.0 |
Amines/metabolism | 4 | 30.0 |
Cohort Studies | 3 | 0.0 |
Multivariate Analysis | 2 | 0.0 |
Oxidative Stress | 2 | 0.0 |
Acetyltransferases/*metabolism | 6 | 7.0 |
Lung Neoplasms/etiology | 2 | 18.0 |
Neoplasms/*etiology | 3 | 11.0 |
Blotting, Southern | 3 | 0.0 |
Cats | 2 | 0.0 |
DNA | 3 | 0.0 |
Liver/*enzymology | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 5 | 0.0 |
Acetyltransferases/*biosynthesis/genetics | 2 | 100.0 |
Animals, Newborn | 2 | 0.0 |
Gene Expression Regulation, Developmental | 2 | 0.0 |
Mutagens/*pharmacokinetics | 2 | 25.0 |
Transfection | 7 | 0.0 |
DNA/analysis | 3 | 0.0 |
Arylamine N-Acetyltransferase/genetics/*metabolism | 3 | 18.0 |
Isoenzymes/genetics/*metabolism | 2 | 2.0 |
Genes, p53/*genetics | 2 | 0.0 |
Colorectal Neoplasms/enzymology/*genetics | 2 | 12.0 |
European Continental Ancestry Group/genetics | 2 | 0.0 |
Tumor Markers, Biological/genetics | 2 | 2.0 |
California | 2 | 4.0 |
Continental Population Groups | 2 | 1.0 |
Prevalence | 2 | 0.0 |
*Variation (Genetics) | 6 | 0.0 |
*RNA Editing | 3 | 7.0 |
Transgenes | 2 | 0.0 |
Arylamine N-Acetyltransferase/metabolism | 3 | 14.0 |
DNA Primers/genetics | 4 | 0.0 |
Leukocytes, Mononuclear/enzymology | 2 | 16.0 |
p-Aminosalicylic Acid/metabolism | 2 | 100.0 |
Ultraviolet Rays | 2 | 0.0 |
Hydrogen-Ion Concentration | 3 | 0.0 |
Cytochrome P-450 Enzyme System/genetics | 3 | 2.0 |
Xenobiotics/*metabolism | 3 | 5.0 |
Polymerase Chain Reaction/*methods | 3 | 0.0 |
Evolution, Molecular | 2 | 0.0 |
Acyltransferases/metabolism | 3 | 23.0 |
Benzidines/metabolism | 2 | 33.0 |
Benzo(a)pyrene/metabolism | 2 | 11.0 |
Biphenyl Compounds/metabolism | 2 | 40.0 |
Oxidation-Reduction | 4 | 0.0 |
Peroxidase/metabolism | 2 | 1.0 |
Biological Markers | 5 | 0.0 |
*Smoking | 2 | 2.0 |
Cytochrome P-450 Enzyme System/*metabolism | 2 | 0.0 |
Hamsters | 9 | 0.0 |
Binding Sites/genetics | 2 | 0.0 |
Mutagenesis, Site-Directed | 2 | 0.0 |
Structure-Activity Relationship | 3 | 0.0 |
Xenobiotics/*pharmacokinetics | 2 | 12.0 |
Gene Expression Regulation | 2 | 0.0 |
Acetyl Coenzyme A/metabolism | 2 | 12.0 |
Adenoma/*genetics | 2 | 2.0 |
Poly A/*metabolism | 2 | 9.0 |
Binding Sites | 2 | 0.0 |
Leukocytes, Mononuclear/metabolism | 2 | 0.0 |
Liver/enzymology | 6 | 1.0 |
Cytochrome P-450 Enzyme System/*biosynthesis/genetics | 2 | 2.0 |
Smoking/metabolism | 2 | 3.0 |
Salmonella typhimurium/genetics | 2 | 14.0 |
DNA, Neoplasm/genetics | 2 | 0.0 |
Cricetulus | 2 | 0.0 |
Chromatography, Ion Exchange | 2 | 0.0 |
Recombinant Proteins/genetics/metabolism | 2 | 0.0 |
Genetic Screening/*methods | 2 | 1.0 |
Polymorphism, Single Nucleotide/genetics | 2 | 0.0 |
4-Aminobenzoic Acid/*metabolism | 3 | 100.0 |
Arylamine N-Acetyltransferase/*blood | 2 | 100.0 |
Leukocytes, Mononuclear/*enzymology | 2 | 8.0 |
Cytochrome P-450 CYP1A2 | 4 | 4.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Oxidoreductases/genetics | 2 | 5.0 |
Uracil/analogs & derivatives/urine | 2 | 25.0 |
Xanthines/urine | 2 | 15.0 |
Escherichia coli/genetics | 2 | 0.0 |
Carcinogens/*pharmacokinetics | 4 | 17.0 |
Fluorenes/*pharmacokinetics | 2 | 100.0 |
RNA, Messenger/metabolism | 3 | 0.0 |
Arylamine N-Acetyltransferase/biosynthesis/*genetics | 2 | 66.0 |
Recombinant Proteins/biosynthesis | 2 | 0.0 |
Mesocricetus | 3 | 1.0 |
*DNA Damage | 3 | 0.0 |
DNA Probes | 2 | 0.0 |
DNA Adducts/analysis/drug effects | 2 | 100.0 |
Statistics | 2 | 0.0 |
